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exercise on cognitive function and brain plasticity (9). However,
because poor adherence to exercise training is relatively com-
mon, effective strategies for optimizing patient adherence are
needed (10).
It also should be noted that, though there is an extensive
literature documenting the value of exercise in patients with
coronary artery disease (CAD), data regarding the significance of
stress-management training in improving clinical outcomes are
limited. A nonrandomized trial of patients with stable CHD
showed that stress-management training was associated with
reduced ischemia, fewer cardiac events, and lower medical costs
compared to usual care controls (11,12). In the absence of data
from large multicenter randomized clinical trials with “hard”
clinical end points, we advocate for smaller studies using interme-
diate biomarkers of cardiovascular risk (13). For example, in a
recent study (14) both exercise and stress-management training
were found to reduce myocardial ischemia and improve vascular
endothelial function, compared to usual care. Furthermore, stress
management was actually superior to exercise training in improv-
ing measures of heart rate variability and baroreflex sensitivity.
These data would strongly support the potential clinical benefits of
both exercise and stress management in the routine care of patients
with CHD.
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Hemodynamic Phenomenon
or Geometric Discrepancy?
The recent study by Li et al. (1) has several limitations. The
absence of information on functional capacities, symptoms, pre-
operative pressure data, or left ventricular (LV) function indices
limits the significance of the data.
Perioperative mortality increases when pulmonary artery
(PA) pressures exceed 60 mm Hg, which is the cutoff in
risk-stratification systems like the Euroscore. A cutoff of 40 mm
Hg overestimates the incidence of severe pulmonary hyperten-
sion (PHT). Significantly, 15 of 40 patients with prosthesis-
patient mismatch (PPM) had postoperative atrial fibrillation
(AF). The difference in mean gradients between the PPM and
non-PPM groups is merely statistical, but insignificant. The
investigators suggest a “simple” strategy of implanting a pros-
thesis to obtain an indexed effective orifice area (EOA) [EOAI]
1.2 cm2/m2. This arbitrary classification based on EOAI has
no surgical significance. There is no mention of valve annular
diameters, which is an important consideration in the choice of
prosthesis size. The EOAIs for the different prosthesis sizes are
unavailable.
Most patients have body surface areas (BSAs) between 1.5 and
2 m2. This translates to absolute EOAs between 1.8 and 2.4 cm2.
The minimum absolute EOA of any size 23 prosthesis is 2.54 cm2,
which produces an EOAI 1.2 cm2/m2. However, a 23-mm
mitral prosthesis is clearly hemodynamically restrictive. Most
surgeons would implant larger valves than these; it follows that no
patient should have PPM if an EOAI of 1.2 cm2/m2 is considered
the minimum! In consequence, the recommendations by Li et al.
(1) are nonspecific and impractical.
Twenty-one of 32 patients with preoperative PHT had PPM.
In essence, the smallest valves were implanted in those with large
BSAs and preoperative PHT. Naturally, many patients would have
residual PHT. Could the investigators have actually undersized the
prosthesis in many patients?
Native annular diameter places a major restriction on the
maximum implantable prosthesis size. Problems with dispropor-
tionately large mitral prostheses include LV outflow obstruction,
restriction of prosthetic mobility, circumflex artery and conduction
system injury. Complications like atrioventricular groove dehis-
cence and ventricular rupture with large valves are every surgeon’s
nightmare. A murine annulus will not take an elephantine pros-
thesis!
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We thank Dr. Shanmugam for his interest in our study (1). Most
of the limitations he raises have been discussed in detail in our
report. We have never suggested that a cutoff of 40 mm Hg was
equivalent to severe pulmonary hypertension. Nonetheless, as we
have also alluded to in our study, such levels of pulmonary
pressures, equivalent to mild/moderate pulmonary hypertension,
have been associated with significantly worse outcomes. Moreover,
the fact that such levels of pressure would persist in patients with
prosthesis-patient mismatch (PPM), whereas they would regress in
most patients without PPM, indeed confirms that levels above 40
mm Hg are clearly abnormal.
The indexed effective orifice area (EOA) is a physiological
parameter that relates to the intrinsic hemodynamic performance
of the prosthesis and has nothing to do with valve annular
diameters. The threshold value of 1.2 cm2/m2 was chosen to
identify PPM because it was the most discriminative value to
identify patients with persisting pulmonary artery hypertension
after mitral valve replacement (MVR), and it is consistent with
previous in vitro and in vivo studies on mitral PPM. As we have
emphasized, the pressure gradient is a much less appropriate
parameter with which to assess the consequences of PPM, espe-
cially in the mitral position, because it is highly influenced by
chronotropic conditions and because mitral flow tends to decrease
when pulmonary resistances are increased.
The statement that “the minimum absolute valve EOA of any
size-23 prosthesis is 2.54 cm2” denotes a gross misunderstanding
of valve prosthesis physiology and is equivalent to saying that all
prostheses of a given labeled size would have similar hemodynamic
performance. Indeed, it is well known that labeled sizes have no
relevance to valve hemodynamics and that they grossly overesti-
mate the actual EOA, which may vary from one type of prosthesis
to another. In this context, it is interesting to note that the normal
reference values of EOA for 27-mm mitral prostheses range from
1.6 to 2.2 cm2 (2). Hence, it is not surprising that PPM defined as
an indexed EOA 1.2 cm2/m2 can be a frequent occurrence in
patients undergoing MVR.
We agree with Dr. Shanmugam that the prevention of PPM in
the mitral position is a particularly demanding challenge for the
surgeon and that there are not as many options as in the aortic
position. Nonetheless, and as we have shown, it is not a rare
occurrence and definitely warrants further documentation. Our
results also provide impetus for the development of better per-
forming mitral prostheses.
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Drug-Eluting Stent
Thrombosis: A Pooled Analysis
With great interest I read the study by Moreno et al. (1) regarding
drug-eluting stent thrombosis. The investigators showed a signif-
icant relation between the rate of drug-eluting stent thrombosis
and the mean stented length in each trial. However, the mean
stented length may not represent the stent length of the actual
cases, especially in these few occurrences of thrombosis (0.5%).
In their study, only 15 cases suffered from drug-eluting stent
thrombosis. Collecting individual patient data will provide the least
biased and most reliable means of addressing questions (2).
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We thank Dr. Kaneda for his interest in our study. We agree with
the affirmation that the mean stented length for each study may
not necessarily represent the stent length of the actual cases of stent
thrombosis. Because of that, as we described in the Methods
section (Statistical Analysis), we contacted the principal investiga-
tors of all studies in which at least one drug-eluting stent
thrombosis was documented, requesting the total stent length for
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